A nomogram to predict the high-risk RS in HR+/HER2-breast cancer patients older than 50 years of age.

ABSTRACT:

Background

The 21-gene recurrence score (RS) testing can predict the prognosis for luminal breast cancer patients. Meanwhile, patients > 50 years with RS > 25 have improved survival with adjuvant chemotherapy. The current study aimed to develop a nomogram with routine parameters to predict RS.

Methods

We included patients diagnosed with hormone receptor (HR)-positive, human epidermal growth factor receptor-2 (HER2)-negative who underwent the 21-gene RS testing and aged > 50 years. The primary outcome was high-risk RS (> 25). Univariate and multivariate analyses were performed to identify significant predictors. A predictive nomogram based on logistic model was developed and evaluated with receiver operating characteristic (ROC) curves. The nomogram was internally validated f

SUBMITTER: Yu J 

PROVIDER: S-EPMC7885620 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature